| Target Price | $130.56 |
| Price | $120.74 |
| Potential | 8.13% |
| Number of Estimates | 29 |
| 29 Analysts have issued a price target Gilead Sciences 2026 . The average Gilead Sciences target price is $130.56. This is 8.13% higher than the current stock price. The highest price target is $150.15 24.36% , the lowest is $98.98 18.02% . | |
| A rating was issued by 36 analysts: 28 Analysts recommend Gilead Sciences to buy, 8 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Gilead Sciences stock has an average upside potential 2026 of 8.13% . Most analysts recommend the Gilead Sciences stock at Purchase. |
30 Analysts have issued a sales forecast Gilead Sciences 2025 . The average Gilead Sciences sales estimate is $29.4b . This is 1.69% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $30.7b 6.26% , the lowest is $27.9b 3.21% .
This results in the following potential growth metrics:
| 2024 | $28.8b | 6.04% |
|---|---|---|
| 2025 | $29.4b | 2.08% |
| 2026 | $30.5b | 3.96% |
| 2027 | $32.2b | 5.66% |
| 2028 | $34.0b | 5.32% |
| 2029 | $35.7b | 5.19% |
| 2030 | $37.5b | 4.99% |
| 2031 | $38.2b | 1.99% |
| 2032 | $38.3b | 0.09% |
16 Analysts have issued an Gilead Sciences EBITDA forecast 2025. The average Gilead Sciences EBITDA estimate is $14.8b . This is 2.44% lower than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $16.8b 10.71% , the lowest is $13.3b 12.42% .
This results in the following potential growth metrics and future EBITDA Margins:
| 2024 | $13.6b | 8.28% |
|---|---|---|
| 2025 | $14.8b | 8.78% |
| 2026 | $15.6b | 5.57% |
| 2027 | $16.6b | 6.03% |
| 2028 | $19.2b | 16.08% |
| 2029 | $20.1b | 4.84% |
| 2030 | $20.2b | 0.22% |
| 2031 | $20.3b | 0.76% |
| 2032 | $21.8b | 6.98% |
| 2024 | 47.28% | 2.12% |
|---|---|---|
| 2025 | 50.38% | 6.56% |
| 2026 | 51.17% | 1.57% |
| 2027 | 51.35% | 0.35% |
| 2028 | 56.59% | 10.20% |
| 2029 | 56.41% | 0.32% |
| 2030 | 53.84% | 4.56% |
| 2031 | 53.19% | 1.21% |
| 2032 | 56.86% | 6.90% |
30 Gilead Sciences Analysts have issued a net profit forecast 2025. The average Gilead Sciences net profit estimate is $10.3b . This is 62.59% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $10.9b 72.54% , the lowest is $9.7b 54.29% .
This results in the following potential growth metrics and future Net Margins:
| 2024 | $480m | 91.53% |
|---|---|---|
| 2025 | $10.3b | 2,037.78% |
| 2026 | $10.9b | 6.07% |
| 2027 | $11.8b | 8.64% |
| 2028 | $12.8b | 8.34% |
| 2029 | $14.1b | 10.05% |
| 2030 | $15.2b | 8.16% |
| 2031 | $15.6b | 2.47% |
| 2032 | $15.3b | 2.03% |
| 2024 | 1.67% | 92.01% |
|---|---|---|
| 2025 | 34.96% | 1,994.25% |
| 2026 | 35.67% | 2.03% |
| 2027 | 36.68% | 2.83% |
| 2028 | 37.73% | 2.86% |
| 2029 | 39.47% | 4.61% |
| 2030 | 40.66% | 3.01% |
| 2031 | 40.85% | 0.47% |
| 2032 | 39.99% | 2.11% |
30 Analysts have issued a Gilead Sciences forecast for earnings per share. The average Gilead Sciences EPS is $8.26 . This is 64.54% higher than earnings per share in the financial year 2024. The highest EPS forecast is $8.77 74.70% , the lowest is $7.84 56.18% .
This results in the following potential growth metrics and future valuations:
| 2024 | $0.38 | 91.56% |
|---|---|---|
| 2025 | $8.26 | 2,073.68% |
| 2026 | $8.76 | 6.05% |
| 2027 | $9.52 | 8.68% |
| 2028 | $10.31 | 8.30% |
| 2029 | $11.35 | 10.09% |
| 2030 | $12.28 | 8.19% |
| 2031 | $12.58 | 2.44% |
| 2032 | $12.33 | 1.99% |
| Current | 24.20 | 97.49% |
|---|---|---|
| 2025 | 14.70 | 39.24% |
| 2026 | 13.86 | 5.71% |
| 2027 | 12.76 | 7.94% |
| 2028 | 11.78 | 7.68% |
| 2029 | 10.70 | 9.17% |
| 2030 | 9.89 | 7.57% |
| 2031 | 9.65 | 2.43% |
| 2032 | 9.85 | 2.07% |
Based on analysts' sales estimates for 2025, the Gilead Sciences stock is valued at an EV/Sales of 5.81 and an P/S ratio of 5.13 .
This results in the following potential growth metrics and future valuations:
| Current | 5.91 | 29.32% |
|---|---|---|
| 2025 | 5.81 | 1.74% |
| 2026 | 5.59 | 3.81% |
| 2027 | 5.29 | 5.35% |
| 2028 | 5.02 | 5.05% |
| 2029 | 4.77 | 4.93% |
| 2030 | 4.55 | 4.75% |
| 2031 | 4.46 | 1.95% |
| 2032 | 4.45 | 0.09% |
| Current | 5.22 | 36.75% |
|---|---|---|
| 2025 | 5.13 | 1.66% |
| 2026 | 4.94 | 3.81% |
| 2027 | 4.67 | 5.36% |
| 2028 | 4.44 | 5.05% |
| 2029 | 4.22 | 4.94% |
| 2030 | 4.02 | 4.75% |
| 2031 | 3.94 | 1.95% |
| 2032 | 3.94 | 0.09% |
Gilead Sciences...
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Citigroup |
Buy
➜
Buy
|
Unchanged | Oct 08 2025 |
| JP Morgan |
Overweight
➜
Overweight
|
Unchanged | Sep 16 2025 |
| RBC Capital |
Sector Perform
➜
Sector Perform
|
Unchanged | Aug 08 2025 |
| UBS |
Neutral
➜
Neutral
|
Unchanged | Aug 08 2025 |
| Truist Securities |
Hold
➜
Buy
|
Upgrade | Aug 08 2025 |
| Needham |
Hold
➜
Buy
|
Upgrade | Jul 25 2025 |
| Needham |
Hold
➜
Hold
|
Unchanged | May 21 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
Citigroup:
Buy
➜
Buy
|
Oct 08 2025 |
|
Unchanged
JP Morgan:
Overweight
➜
Overweight
|
Sep 16 2025 |
|
Unchanged
RBC Capital:
Sector Perform
➜
Sector Perform
|
Aug 08 2025 |
|
Unchanged
UBS:
Neutral
➜
Neutral
|
Aug 08 2025 |
|
Upgrade
Truist Securities:
Hold
➜
Buy
|
Aug 08 2025 |
|
Upgrade
Needham:
Hold
➜
Buy
|
Jul 25 2025 |
|
Unchanged
Needham:
Hold
➜
Hold
|
May 21 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


